Embla Medical hf.
OSSFF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $854,889 | $785,683 | $718,650 | $718,669 |
| % Growth | 8.8% | 9.3% | -0% | – |
| Cost of Goods Sold | $354,642 | $331,291 | $310,708 | $297,599 |
| Gross Profit | $500,247 | $454,392 | $407,942 | $421,070 |
| % Margin | 58.5% | 57.8% | 56.8% | 58.6% |
| R&D Expenses | $35,340 | $33,397 | $29,377 | $26,893 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $352,154 | $333,534 | $293,425 | $298,553 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $387,494 | $366,931 | $322,802 | $325,446 |
| Operating Income | $112,753 | $87,461 | $85,140 | $95,624 |
| % Margin | 13.2% | 11.1% | 11.8% | 13.3% |
| Other Income/Exp. Net | -$22,190 | -$11,454 | -$28,968 | -$8,984 |
| Pre-Tax Income | $90,563 | $76,007 | $56,172 | $86,640 |
| Tax Expense | $21,603 | $17,206 | $12,962 | $20,984 |
| Net Income | $68,278 | $58,389 | $42,513 | $63,994 |
| % Margin | 8% | 7.4% | 5.9% | 8.9% |
| EPS | 0.16 | 0.14 | 0.1 | 0.15 |
| % Growth | 14.3% | 40% | -33.3% | – |
| EPS Diluted | 0.16 | 0.14 | 0.1 | 0.15 |
| Weighted Avg Shares Out | 426,644 | 420,297 | 417,758 | 422,161 |
| Weighted Avg Shares Out Dil | 426,659 | 420,318 | 417,831 | 422,795 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,966 | $3,448 | $779 | $168 |
| Interest Expense | $24,746 | $20,720 | $12,947 | $12,774 |
| Depreciation & Amortization | $55,973 | $49,920 | $49,365 | $51,528 |
| EBITDA | $167,942 | $143,249 | $118,127 | $150,546 |
| % Margin | 19.6% | 18.2% | 16.4% | 20.9% |